middle.news
Invex Therapeutics Advances Exenatide Research with New Alzheimer’s Model Data
12:44pm on Friday 24th of April, 2026 AEST
•
Healthcare
Read Story
Invex Therapeutics Advances Exenatide Research with New Alzheimer’s Model Data
12:44pm on Friday 24th of April, 2026 AEST
Key Points
Exenatide reduces neurofilament light chain and inflammatory cytokines in ADBrain™ model
Cash reserves slightly down to $4.5 million with operating outflows easing
Company secretary resigns amid ongoing corporate restructuring
Further investigation planned on amyloid beta effects in preclinical studies
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Invex Therapeutics (ASX:IXC)
OPEN ARTICLE